All policies issued or renewed in Oklahoma on or after November 1, 2025, must comply with the cancer testing provisions of SB 109. Specifically, a group health insurance policy must provide coverage for clinical gene testing of inherited gene mutations for individuals with a personal or family history of cancer. Further, the test must be ordered or recommended by a healthcare provider in accordance with the most recent version of the NCCN clinical practice recommendations that are Category 2A or higher, or in accordance with other nationally recognized clinical practice guidelines. The coverage must not be subject to any deductibles, copayments, or coinsurance.
Insurers are responsible for bringing applicable fully insured plans into compliance. Employer plan sponsors should be aware of the changes.
Read the full legislation: SB 109.